Literature DB >> 24296348

The role of MIZ-1 in MYC-dependent tumorigenesis.

Katrin E Wiese1, Susanne Walz, Björn von Eyss, Elmar Wolf, Dimitris Athineos, Owen Sansom, Martin Eilers.   

Abstract

A hallmark of MYC-transformed cells is their aberrant response to antimitogenic signals. Key examples include the inability of MYC-transformed cells to arrest proliferation in response to antimitogenic signals such as TGF-β or DNA damage and their inability to differentiate into adipocytes in response to hormonal stimuli. Given the plethora of antimitogenic signals to which a tumor cell is exposed, it is likely that the ability to confer resistance to these signals is central to the transforming properties of MYC in vivo. At the same time, the inability of MYC-transformed cells to halt cell-cycle progression on stress may establish a dependence on mutations that impair or disable apoptosis. We propose that the interaction of MYC with the zinc finger protein MIZ-1 mediates resistance to antimitogenic signals. In contrast to other interactions of MYC, there is currently little evidence that MIZ-1 associates with MYC in normal, unperturbed cells. The functional interaction of both proteins becomes apparent at oncogenic expression levels of MYC and association with MIZ-1 mediates both oncogenic functions of MYC as well as tumor-suppressive responses to oncogenic levels of MYC.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24296348      PMCID: PMC3839600          DOI: 10.1101/cshperspect.a014290

Source DB:  PubMed          Journal:  Cold Spring Harb Perspect Med        ISSN: 2157-1422            Impact factor:   6.915


  56 in total

1.  A beta-sheet interaction interface directs the tetramerisation of the Miz-1 POZ domain.

Authors:  Mark A Stead; Chi H Trinh; James A Garnett; Stephen B Carr; Andrew J Baron; Thomas A Edwards; Stephanie C Wright
Journal:  J Mol Biol       Date:  2007-08-21       Impact factor: 5.469

2.  Miz1 and HectH9 regulate the stability of the checkpoint protein, TopBP1.

Authors:  Steffi Herold; Andreas Hock; Barbara Herkert; Katrien Berns; Jasper Mullenders; Roderick Beijersbergen; Rene Bernards; Martin Eilers
Journal:  EMBO J       Date:  2008-10-16       Impact factor: 11.598

Review 3.  An overview of MYC and its interactome.

Authors:  Maralice Conacci-Sorrell; Lisa McFerrin; Robert N Eisenman
Journal:  Cold Spring Harb Perspect Med       Date:  2014-01-01       Impact factor: 6.915

4.  Repression of p15INK4b expression by Myc through association with Miz-1.

Authors:  P Staller; K Peukert; A Kiermaier; J Seoane; J Lukas; H Karsunky; T Möröy; J Bartek; J Massagué; F Hänel; M Eilers
Journal:  Nat Cell Biol       Date:  2001-04       Impact factor: 28.824

Review 5.  The quest for the 1p36 tumor suppressor.

Authors:  Anindya Bagchi; Alea A Mills
Journal:  Cancer Res       Date:  2008-04-15       Impact factor: 12.701

6.  Nucleophosmin interacts directly with c-Myc and controls c-Myc-induced hyperproliferation and transformation.

Authors:  Zhaoliang Li; David Boone; Stephen R Hann
Journal:  Proc Natl Acad Sci U S A       Date:  2008-11-24       Impact factor: 11.205

Review 7.  MYC degradation.

Authors:  Amy S Farrell; Rosalie C Sears
Journal:  Cold Spring Harb Perspect Med       Date:  2014-03-01       Impact factor: 6.915

8.  Modelling Myc inhibition as a cancer therapy.

Authors:  Laura Soucek; Jonathan Whitfield; Carla P Martins; Andrew J Finch; Daniel J Murphy; Nicole M Sodir; Anthony N Karnezis; Lamorna Brown Swigart; Sergio Nasi; Gerard I Evan
Journal:  Nature       Date:  2008-08-17       Impact factor: 49.962

9.  Mule/Huwe1/Arf-BP1 suppresses Ras-driven tumorigenesis by preventing c-Myc/Miz1-mediated down-regulation of p21 and p15.

Authors:  Satoshi Inoue; Zhenyue Hao; Andrew J Elia; David Cescon; Lily Zhou; Jennifer Silvester; Bryan Snow; Isaac S Harris; Masato Sasaki; Wanda Y Li; Momoe Itsumi; Kazuo Yamamoto; Takeshi Ueda; Carmen Dominguez-Brauer; Chiara Gorrini; Iok In Christine Chio; Jillian Haight; Annick You-Ten; Susan McCracken; Andrew Wakeham; Danny Ghazarian; Linda J Z Penn; Gerry Melino; Tak W Mak
Journal:  Genes Dev       Date:  2013-05-15       Impact factor: 11.361

10.  Physical interaction between MYCN oncogene and polycomb repressive complex 2 (PRC2) in neuroblastoma: functional and therapeutic implications.

Authors:  Daisy Corvetta; Olesya Chayka; Samuele Gherardi; Cosimo W D'Acunto; Sandra Cantilena; Emanuele Valli; Izabela Piotrowska; Giovanni Perini; Arturo Sala
Journal:  J Biol Chem       Date:  2013-01-28       Impact factor: 5.157

View more
  50 in total

Review 1.  Microenvironment abnormalities and lymphomagenesis: Immunological aspects.

Authors:  Joseph G Taylor; John G Gribben
Journal:  Semin Cancer Biol       Date:  2015-07-29       Impact factor: 15.707

Review 2.  An overview of MYC and its interactome.

Authors:  Maralice Conacci-Sorrell; Lisa McFerrin; Robert N Eisenman
Journal:  Cold Spring Harb Perspect Med       Date:  2014-01-01       Impact factor: 6.915

Review 3.  Genome recognition by MYC.

Authors:  Arianna Sabò; Bruno Amati
Journal:  Cold Spring Harb Perspect Med       Date:  2014-02-01       Impact factor: 6.915

Review 4.  MYC cofactors: molecular switches controlling diverse biological outcomes.

Authors:  Stephen R Hann
Journal:  Cold Spring Harb Perspect Med       Date:  2014-06-17       Impact factor: 6.915

5.  MYC inhibits the clock and supports proliferation.

Authors:  Anton Shostak; Axel Diernfellner; Michael Brunner
Journal:  Cell Cycle       Date:  2016-09-07       Impact factor: 4.534

6.  Repression of SRF target genes is critical for Myc-dependent apoptosis of epithelial cells.

Authors:  Katrin E Wiese; Heidi M Haikala; Björn von Eyss; Elmar Wolf; Cyril Esnault; Andreas Rosenwald; Richard Treisman; Juha Klefström; Martin Eilers
Journal:  EMBO J       Date:  2015-04-20       Impact factor: 11.598

7.  MYC regulates the antitumor immune response through CD47 and PD-L1.

Authors:  Stephanie C Casey; Ling Tong; Yulin Li; Rachel Do; Susanne Walz; Kelly N Fitzgerald; Arvin M Gouw; Virginie Baylot; Ines Gütgemann; Martin Eilers; Dean W Felsher
Journal:  Science       Date:  2016-03-10       Impact factor: 47.728

Review 8.  MYC: a multipurpose oncogene with prognostic and therapeutic implications in blood malignancies.

Authors:  Seyed Esmaeil Ahmadi; Samira Rahimi; Bahman Zarandi; Rouzbeh Chegeni; Majid Safa
Journal:  J Hematol Oncol       Date:  2021-08-09       Impact factor: 17.388

Review 9.  MYC and the control of DNA replication.

Authors:  David Dominguez-Sola; Jean Gautier
Journal:  Cold Spring Harb Perspect Med       Date:  2014-06-02       Impact factor: 6.915

10.  Neural stem cell-encoded temporal patterning delineates an early window of malignant susceptibility in Drosophila.

Authors:  Karine Narbonne-Reveau; Elodie Lanet; Caroline Dillard; Sophie Foppolo; Ching-Huan Chen; Hugues Parrinello; Stéphanie Rialle; Nicholas S Sokol; Cédric Maurange
Journal:  Elife       Date:  2016-06-14       Impact factor: 8.140

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.